Helmholtz Gemeinschaft


Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories

Item Type:Article
Title:Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories
Creators Name:Gross, C.C. and Schulte-Mecklenbeck, A. and Steinberg, O.V. and Wirth, T. and Lauks, S. and Bittner, S. and Schindler, P. and Baranzini, S.E. and Groppa, S. and Bellmann-Strobl, J. and Bünger, N. and Chien, C. and Dawin, E. and Eveslage, M. and Fleischer, V. and Gonzalez-Escamilla, G. and Gisevius, B. and Haas, J. and Kerschensteiner, M. and Kirstein, L. and Korsukewitz, C. and Lohmann, L. and Lünemann, J.D. and Luessi, F. and Meyer Zu Hörste, G. and Motte, J. and Ruck, T. and Ruprecht, K. and Schwab, N. and Steffen, F. and Meuth, S.G. and Paul, F. and Wildemann, B. and Kümpfel, T. and Gold, R. and Hahn, T. and Zipp, F. and Klotz, L. and Wiendl, H.
Abstract:One of the biggest challenges in managing multiple sclerosis is the heterogeneity of clinical manifestations and progression trajectories. It still remains to be elucidated whether this heterogeneity is reflected by discrete immune signatures in the blood as a surrogate of disease pathophysiology. Accordingly, individualized treatment selection based on immunobiological principles is still not feasible. Using two independent multicentric longitudinal cohorts of patients with early multiple sclerosis (n = 309 discovery and n = 232 validation), we were able to identify three distinct peripheral blood immunological endophenotypes by a combination of high-dimensional flow cytometry and serum proteomics, followed by unsupervised clustering. Longitudinal clinical and paraclinical follow-up data collected for the cohorts revealed that these endophenotypes were associated with disease trajectories of inflammation versus early structural damage. Investigating the capacity of immunotherapies to normalize endophenotype-specific immune signatures revealed discrete effect sizes as illustrated by the limited effect of interferon-β on endophenotype 3-related immune signatures. Accordingly, patients who fell into endophenotype 3 subsequently treated with interferon-β exhibited higher disease progression and MRI activity over a 4-year follow-up compared with treatment with other therapies. We therefore propose that ascertaining a patient's blood immune signature before immunomodulatory treatment initiation may facilitate prediction of clinical disease trajectories and enable personalized treatment decisions based on pathobiological principles.
Keywords:Endophenotypes, Interferon-beta, Multiple Sclerosis, Multiple Sclerosis / Genetics
Source:Science Translational Medicine
Publisher:American Association for the Advancement of Science
Page Range:eade8560
Date:March 2024
Official Publication:https://doi.org/10.1126/scitranslmed.ade8560
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library